DEVELOP CGMP TECHNOLOGY FOR CRISPR/CAS GENOME EDITING OF CELLS FOR USE IN CELL-BASED IMMUNOTHERAPY FOR CANCER

Leidos Biomedical Research, Inc., Frederick MD

Investigators

Abstract

Support to develop cGMP manufacturing capability for non-viral, genome editing of immune cells for use in cancer cell therapy indications.